Esperion Therapeutics: Past The Turnaround, Waiting On Guidelines
Source: SeekingAlpha
2026-02-17 10:02:27 ET
Investment Thesis
Esperion Therapeutics, Inc. ( ESPR ) is a successful turnaround story, and it has nearly doubled on the basis. We must understand, though, that while the share price has recovered, its commercial turnaround is still an ongoing event. So the stock is right now in a waiting phase rather than a momentum phase. What it is waiting for - that key catalyst - is US guideline inclusion....
Read the full article on Seeking Alpha
For further details see:
Esperion Therapeutics: Past The Turnaround, Waiting On Guidelines
Esperion Therapeutics Inc.
NASDAQ: ESPR
ESPR Trading
-0.55% G/L:
$2.6701 Last:
969,700 Volume:
$2.67 Open:
ESPR Latest News
March 05, 2026 07:00:00 am
HLS Therapeutics Announces NILEMDOTM (bempedoic acid) is now available in Canada for the Reduction of LDL-Cholesterol in Patients at Risk of Cardiovascular Disease
March 03, 2026 06:00:00 am
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst(TM) (bumetanide nasal spray)
February 24, 2026 08:00:00 am
Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10
ESPR Stock Data
$804,448,466
234,999,359
0.16%
70
N/A
Pharmaceuticals
Healthcare
US
Ann Arbor
